Εμφανίζονται 1 - 20 Αποτελέσματα από 484 για την αναζήτηση '"СЕРДЕЧНО-СОСУДИСТЫЙ РИСК"', χρόνος αναζήτησης: 0,97δλ Περιορισμός αποτελεσμάτων
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
    Academic Journal

    Συγγραφείς: Азимова , Севинч

    Πηγή: Eurasian Journal of Medical and Natural Sciences; Vol. 5 No. 10 Part 2 (2025): Eurasian Journal of Medical and Natural Sciences; 123-130 ; Евразийский журнал медицинских и естественных наук; Том 5 № 10 Part 2 (2025): Евразийский журнал медицинских и естественных наук; 123-130 ; Yevrosiyo tibbiyot va tabiiy fanlar jurnali; Jild 5 Nomeri 10 Part 2 (2025): Евразийский журнал медицинских и естественных наук; 123-130 ; 2181-287X

    Περιγραφή αρχείου: application/pdf

  7. 7
  8. 8
    Academic Journal

    Συνεισφορές: Авторы заявляют об отсутствии финансирования исследования.

    Πηγή: Complex Issues of Cardiovascular Diseases; Том 14, № 4 (2025); 6-17 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 14, № 4 (2025); 6-17 ; 2587-9537 ; 2306-1278

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.nii-kpssz.com/jour/article/view/1733/1067; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1733/2185; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1733/2186; Vos T., Lim S.S., Abbafati C., Abbas K.M., et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258): 1204–1222. doi:10.1016/S0140–6736(20)30925–9.; Бойцов С.А., Погосова Н.В., Аншелес А.А., Бадтиева В.А., и соавт. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023; 28(5): 119–249. doi:10.15829/1560–4071–2023–5452.; Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart. J. 2021; 42(34): 3227–3337. doi:10.1093/eurheartj/ehab484.; Бойцов С.А., Погосова Н.В., Бубнова М.Г., Драпкина О.М., и соавт. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018; 23(6): 7–122. doi:10.15829/1560–4071–2018–6–7–122.; Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart. J. 2003; 24(11): 987–1003. doi:10.1016/s0195–668x(03)00114–3.; Балахонова Т.В., Ершова А.И., Ежов М.В., Барбараш О.Л., и соавт. Фокусированное ультразвуковое исследование сосудов. Консенсус Российских экспертов. Кардиоваскулярная терапия и профилактика. 2022; 21(7): 105–126. doi:10.15829/1728–8800–2022–3333.; Stork S., van den Beld A.W., von Schacky C., Angermann C.E., et al. Carotid artery plaque burden, stiffness, and mortality risk in elderly men: a prospective, population-based cohort study. Circulation. 2004; 110(3): 344–8. doi:10.1161/01.CIR.0000134966.10793.C9.; Lamina C., Meisinger C., Heid I.M., Lowel H., et al. Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. Eur. Heart. J. 2006; 27(21): 2580–7. doi:10.1093/eurheartj/ehl228.; Yang C.W., Guo Y.C., Li C.I., Liu C.S., et al. Subclinical Atherosclerosis Markers of Carotid Intima-Media Thickness, Carotid Plaques, Carotid Stenosis, and Mortality in Community-Dwelling Adults. Int. J. Environ. Res. Public. Health. 2020; 17(13): 4745. doi:10.3390/ijerph17134745.; Bérard E., Bongard V., Ruidavets J.B., Amar J. Pulse wave velocity, pulse pressure and number of carotid or femoral plaques improve prediction of cardiovascular death in a population at low risk. J. Hum. Hypertens. 2013; 27(9): 529–34. doi:10.1038/jhh.2013.8.; Чазова И.Е., Трубачева И.А., Жернакова Ю.В., Ощепкова Е.В., и соавт. Распространенность артериальной гипертонии как фактора риска сердечно-сосудистых заболеваний в крупном городе сибирского федерального округа. Системные гипертензии. 2013; 10(4): 30–37.; Жернакова Ю.В., Кавешников В.С., Серебрякова В.Н., Трубачева И.А., и соавт. Распространенность каротидного атеросклероза в неорганизованной популяции Томска. Системные гипертензии. 2014; 11(4): 37–42.; Кавешников В.С., Серебрякова В.Н., Трубачева И.А., Шальнова С.А. Выраженность каротидного атеросклероза у взрослого неорганизованного населения. Рациональная фармакотерапия в кардиологии. 2019; 15(1): 84–89. doi:10.20996/1819–6446–2019–15–1–84–89.; Бойцов С.А., Карпов Ю.А., Кухарчук В.В., Рогоза А.Н., и соавт. Проблемы выявления лиц с высоким сердечно–сосудистым риском и возможные пути их решения. Атеросклероз и дислипидемии. 2010; 1 (1): 8–14.; Touboul P.J., Hennerici M.G., Meairs S., Adams H., et al. Mannheim carotid intima-media thickness and plaque consensus (2004–2006–2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc. Dis. 2012; 34(4): 290–6. doi:10.1159/000343145.; Johri A.M., Nambi V., Naqvi T.Z., Feinstein S.B., et al. Recommendations for the Assessment of Carotid Arterial Plaque by Ultrasound for the Characterization of Atherosclerosis and Evaluation of Cardiovascular Risk: From the American Society of Echocardiography. J. Am. Soc. Echocardiogr. 2020; 33(8): 917–933. doi:10.1016/j.echo.2020.04.021.; Li W., Wang Y., Chen S., Zhao J., et al. Evaluation of Carotid Artery Atherosclerosis and Arterial Stiffness in Cardiovascular Disease Risk: An Ongoing Prospective Study From the Kailuan Cohort. Front. Cardiovasc. Med. 2022; 9: 812652. doi:10.3389/fcvm.2022.812652.; Polak J.F., Szklo M., Kronmal R.A., Burke G.L., et al. The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis. J. Am. Heart. Assoc. 2013; 2(2): e000087. doi:10.1161/JAHA.113.000087.; Ершова А.И., Мешков А.Н., Деев А.Д., Александрова Е.Л., и соавт. Атеросклеротическая бляшка в сонных артериях как маркер риска развития сердечно-сосудистых событий в популяции среднего возраста. Кардиоваскулярная терапия и профилактика. 2018; 17(4): 34–39. doi:10.15829/1728–8800–2018–4–34–39.; Sillesen H., Sartori S., Sandholt B., Baber U., et al. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. Eur. Heart. J. Cardiovasc. Imaging. 2018; 19(9): 1042–1050. doi:10.1093/ehjci/jex239.; Nambi V., Chambless L., Folsom A.R., He M., et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J. Am. Coll. Cardiol. 2010; 55(15): 1600–7. doi:10.1016/j.jacc.2009.11.075.; Parkkila K., Kesäniemi Y.A., Ukkola O. Comparing ultrasonographically assessed carotid and abdominal aorta plaques in cardiovascular disease risk estimation. BMC. Cardiovasc. Disord. 2023; 23(1): 245. doi:10.1186/s12872–023–03264–1.; Guaricci A.I., Lorenzoni V., Guglielmo M., Mushtaq S., et al. Prognostic relevance of subclinical coronary and carotid atherosclerosis in a diabetic and nondiabetic asymptomatic population. Clin. Cardiol. 2018; 41(6): 769–777. doi:10.1002/clc.22952.; Romanens M., Adams A., Wenger M., Warmuth W. Prognostic impact of carotid plaque imaging using total plaque area added to SCORE2 in middle-aged subjects: the ARteris Cardiovascular Outcome (ARCO) cohort study. Swiss. Med. Wkly. 2024; 154: 3735. doi:10.57187/s.3735.; Nicolaides A.N., Panayiotou A.G., Griffin M., Tyllis T., et al. Arterial Ultrasound Testing to Predict Atherosclerotic Cardiovascular Events. J. Am. Coll. Cardiol. 2022; 79(20): 1969–1982. doi:10.1016/j.jacc.2022.03.352.

  9. 9
    Academic Journal

    Συνεισφορές: Авторы заявляют об отсутствии финансирования исследования.

    Πηγή: Complex Issues of Cardiovascular Diseases; Том 14, № 2 (2025); 11-20 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 14, № 2 (2025); 11-20 ; 2587-9537 ; 2306-1278

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.nii-kpssz.com/jour/article/view/1387/1021; Kubanov A.A., Bogdanova E.E. Epidemiology of psoriasis among the elderly population and volume of specialized medical care provided to patients with psoriasis in the Russian Federation in 2010–2019. Vestn Dermatol Venerol. 2020; 96: 7–18. doi:10.25208/vdv1171-2020-96-5-07-18.; Rendon A., Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019; 20: 1475. doi:10.3390/ijms20061475.; Andújar I., Esplugues J.V., García-Martínez P. Looking beyond the Skin: Pathophysiology of Cardiovascular Comorbidity in Psoriasis and the Protective Role of Biologics. Pharmaceuticals. 2022; 15: 1101. doi:10.3390/PH15091101.; Liu L., Cui S., Liu M., Huo X., Zhang G., Wang N. Psoriasis Increased the Risk of Adverse Cardiovascular Outcomes: A New Systematic Review and Meta-Analysis of Cohort Study. Front Cardiovasc Med. 2022; 9: 1–12 doi:10.3389/fcvm.2022.829709.; Gonzalez-Cantero A., Reddy A.S., Dey A.K., Gonzalez-Cantero J., Munger E., Rodante J., Sanchez-Moya A.I., Perez-Hortet C., et al. Underperformance of clinical risk scores in identifying imaging-based high cardiovascular risk in psoriasis: results from two observational cohorts. Eur J Prev Cardiol. 2022; 29: 591–598. doi:10.1093/eurjpc/zwaa033.; Mw D., Hajdarbegovic B.E. Drug-induced psoriasis: clinical perspectives. Psoriasis: Targets and Therapy. 2017; 7: 87–94. doi:10.2147/PTT.S126727.; Свечникова Е.В., Моржанаева М.А., Щепкина Е.В. Оценка затрат на лечение псориаза средних и тяжелых форм при коморбидных патологиях. Вестник медицинского института непрерывного образования. 2024; 4: 117–122. doi:10.36107/2782-1714_2024-4-2-107-116.; Zhao S.S., Yiu Z.Z.N., Barton A., Bowes J. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study. JAMA Dermatol. 2023; 159: 275–280. doi:10.1001/JAMADERMATOL.2022.6051.; Клинические рекомендации по ведению больных псориазом. Общероссийская общественная организация «Российское общество дерматовенерологов и косметологов», https://www.rodv.ru/upload/iblock/aa2/aa20a2fc65b13df3899140167777092d.pdf (2023).; Rungapiromnan W., Mason K.J., Lunt M., McElhone K., Burden A.D., Rutter M.K., Warren R.B., Griffiths C.E.M., Ashcroft D.M.; BADBIR Study Group. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. J Eur Acad Dermatol Venereol. 2020; 34: 769–778. doi:10.1111/jdv.16018.; Rungapiromnan W., Yiu Z.Z.N., Warren R.B., Griffiths C.E.M., Ashcroft D.M. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017; 176: 890–901. doi:10.1111/BJD.14964.; Terui H., Asano Y. Biologics for Reducing Cardiovascular Risk in Psoriasis Patients. J Clin Med. 12. Epub ahead of print 1 February 2023. doi:10.3390/JCM12031162.; Elnabawi Y.A., Dey A.K., Goyal A., Groenendyk J.W., Chung J.H., Belur A.D., Rodante J., Harrington C.L., et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019; 115: 721–728. doi:10.1093/CVR/CVZ009.; Schüler R., Brand A., Klebow S., Wild J., Veras F.P., Ullmann E., Roohani S., Kolbinger F., et al. Antagonization of IL-17A Attenuates Skin Inflammation and Vascular Dysfunction in Mouse Models of Psoriasis. J Invest Dermatol. 2019; 139: 638–647. doi:10.1016/J.JID.2018.09.021.; Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H., Ballantyne C., Fonseca F., Nicolau J.,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; 377: 1119–1131. doi:10.1056/NEJMoa1707914.; Abbas A., Gregersen I., Holm S., Daissormont I., Bjerkeli V., Krohg-Sørensen K., Skagen K.R., Dahl T.B., et al. Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23/interleukin 17 axis. Stroke. 2015; 46: 793–799. doi:10.1161/STROKEAHA.114.006516.; Subramanian M., Thorp E., Tabas I. Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling. Circ Res. 2015; 116: e13–e24 doi:10.1161/CIRCRESAHA.116.304794.; Madhur M.S., Funt S.A., Li L., Vinh A., Chen W., Lob H.E., Iwakura Y., Blinder Y., Rahman A., Quyyumi A.A., Harrison D.G. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol. 2011; 31: 1565–1572 doi:10.1161/ATVBAHA.111.227629.; Ryan C., Leonardi C.L., Krueger J.G., Kimball A.B., Strober B.E., Gordon K.B., Langley R.G., de Lemos J.A., Daoud Y., et al. Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events: A Meta-analysis of Randomized Controlled Trials. JAMA. 2011; 306: 864–871 doi:10.1001/JAMA.2011.1211.; Madhur M.S., Lob H.E., McCann L.A., Iwakura Y., Blinder Y., Guzik T.J., Harrison D.G. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010; 55: 500–507 doi:10.1161/HYPERTENSIONAHA.109.145094.; Российское кардиологическое общество (РКО). Артериальная гипертензия у взрослых. Клинические рекомендации, 2022. 138.; Российское кардиологическое общество (РКО). Стабильная ишемическая болезнь сердца. Клинические рекомендации, 2022. Режим доступа: https://scardio.ru/content/Guidelines/Proekt_2023_SIBS.pdf (дата обращения 20.02.2025); Российское кардиологическое общество (РКО). Нарушения липидного обмена. Клинические рекомендации, 2023. Режим доступа: https://cardioc.ru/spetsialistam/klinicheskie-rekomendatsii/2023/2023_narusheniya_lo.pdf (дата обращения 20.02.2025); SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: Estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021; 42: 2455–2467 doi:10.1093/eurheartj/ehab312.; Кузьмина О.А., Миронова О.Ю., Лепехова А.А., Фомин В.В. Распространенность артериальной гипертензии среди больных псориазом в клинической практике. Consilium Medicum. 2022;24(10):763-766. doi:10.26442/20751753.2022.10.201926; Holmes M.V., Millwood I.Y., Kartsonaki C., Hill M.R., Bennett D.A., Boxall R., Guo Y., Xu X., et al. Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke. J Am Coll Cardiol. 2018; 71: 620 doi:10.1016/J.JACC.2017.12.006.; El Khoudary S.R., Shields K.J., Janssen I., Hanley C., Budoff M.J., Barinas-Mitchell E., Everson-Rose S.A., Powell L.H., Matthews K.A. Cardiovascular fat, menopause, and sex hormones in women: The SWAN cardiovascular fat ancillary study. J Clin Endocrinol Metab. 2015; 100: 3304–3312 doi:10.1210/JC.2015-2110.; Barbieri J.S., Beidas R.S., Gondo G.C., Fishman J., Williams N.J., Armstrong A.W., Ogdie A.R., Mehta N., Gelfand J.M. Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease. JAMA Dermatol. 2022;158(3):252-259. doi:10.1001/jamadermatol.2021.4467.

  10. 10
    Academic Journal

    Πηγή: Siberian Journal of Clinical and Experimental Medicine; Том 40, № 1 (2025); 166-176 ; Сибирский журнал клинической и экспериментальной медицины; Том 40, № 1 (2025); 166-176 ; 2713-265X ; 2713-2927

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.sibjcem.ru/jour/article/view/2645/1060; Ward M.M. Lifetime risks of valvular heart disease and pacemaker use in patients with ankylosing spondylitis. J. Am. Heart Assoc. 2018;7:e010016. https://doi.org/10.1161/jaha.118.010016; Bhattad P.B., Kulkarni M., Patel P.D., Roumia M. Cardiovascular morbidity in ankylosing spondylitis: a focus on inflammatory cardiac disease. Cureus. 2022;14(6):e25633. https://doi.org/10.7759/cureus.25633; Navarini L., Currado D., Marino A., Di Donato S., Biaggi A., Caso F. et al. Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. Sci. Rep. 2022;7(12):7498. https://doi.org/10.1038/s41598-022-11640-8; Lai Y., Zhang Y., Mo S. Ma J., Ni T., Lei Z. et al. Prevalence of comorbidities and risk factors in spondyloarthritis: results of a cross-sectional study. Ann. Rheum. Dis. 2022;81:e43. https://doi.org/10.1136/annrheumdis-2020-217313; Chetrit M., Khan M.A., Kapadia S. State of the art management of aortic valve disease in ankylosing spondylitis. Curr. Rheumatol. Rep. 2020;22(6):23. https://doi.org/10.1007/s11926-020-00898-4; Zhao S.S., Pittam B., Harrison N.L., Ahmed A.E., Goodson N.J., Hughes D.M. Diagnostic delay in axial spondyloarthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2021;60(4):1620– 1628. https://doi.org/10.1093/rheumatology/keaa807; Buleu F., Sirbu E., Caraba A., Dragan S. Heart involvement in inflammatory rheumatic diseases: a systematic literature review. Medicina (Kaunas). 2019;55(6):249. https://doi.org/10.3390/medicina55060249; Bolaji O., Oriaifo O., Adabale O., Dilibe A., Kuruvada K., Ouedraogo F. et al. A meta-analysis of left ventricular dysfunction in ankylosing spondylitis. J. Clin. Hypertens. (Greenwich). 2024;26(7):772–788. https://doi.org/10.3390/medicina55060249; Zhang M., Zhang H., Dai D., Shen B., Ruan D. Risk factors and clinical significance of ankylosing spondylitis combined with early-onset coronary heart disease. Altern. Ther. Health Med. 2024:AT10104. Online ahead of print.; Годзенко А.А., Корсакова Ю.О., Румянцева О.А., Бочкова А.Г., Бадокин В.В., Эрдес Ш.Ф. Прогрессирование патологии аорты и клапанов сердца у больных анкилозирующим спондилитом. Научно-практическая ревматология. 2017;55(5):509–513. https://doi.org/10.14412/1995-4484-2017-509-513; Sherlock J.P., Joyce-Shaikh B., Turner S.P., Chao C.C., Sathe M., Grein J. et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4–CD8– entheseal resident T cells. Nat. Med. 2012;18(7):1069– 1076. https://doi.org/10.1038/nm.2817; Reinhardt A., Yevsa T., Worbs T., Lienenklaus S., Sandrock I., Oberdörfer L. et al. Interleukin-23–dependent γ/δ T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice. Arthritis Rheumatol. 2016;68(10):2476–2486. https://doi.org/10.1002/art.39732; Balčiūnaitė A., Budrikis A., Rumbinaitė E., Sabaliauskienė J., Patamsytė V., Lesauskaitė V. Ankylosing spondyloarthritis resulting severe aortic insufficiency and aortitis: exacerbation of ankylosing spondyloarthritis and stenosis of the main left coronary artery after mechanical aortic valve implantation with cardiopulmonary bypass. Case Rep. Rheumatol. 2020;2020:9538527. https://doi.org/10.1155/2020/9538527; Huffer L.L., Furgerson J.L. Aortic root dilatation with sinus of Valsalva and coronary artery aneurysms associated with ankylosing spondylitis. Tex. Heart Inst. J. 2006;33(1):70–73.; Bengtsson K., Klingberg E., Deminger A., Wallberg H., Jacobsson L.T.H., Bergfeldt L. et al. Cardiac conduction disturbances in patients with ankylosing spondylitis: results from a 5-year follow-up cohort study. RMD Open. 2019;5(2):e001053. https://doi.org/10.1136/rmdopen-2019-001053; Fakih O., Desmarets M., Martin B., Prati C., Wendling D., Monnet E. et al. Impact of NSAIDs on 8-year cumulative incidence of major cardiovascular events in patients with ankylosing spondylitis: a nationwide study. Rheumatology (Oxford). 2023;62(10):3317–3322. https://doi.org/10.1093/rheumatology/kead072; Kim J.W., Yoon J.S., Park S., Kim H., Lee J.S., Choe J.Y. Risk of cardiovascular disease with high-dose versus low-dose use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis. Ann. Rheum. Dis. 2024;83(8):1028–1033. https://doi.org/10.1136/ard-2023-225406; Liew J.W., Treu T., Park Y., Ferguson J.M., Rosser M.A., Ho Y.L. et al. The association of TNF inhibitor use with incident cardiovascular events in radiographic axial spondyloarthritis. Semin. Arthritis Rheum. 2024;68:152482. https://doi.org/10.1016/j.semarthrit.2024.152482; Genovese M.C., Mysler E., Tomita T., Papp K.A., Salvarani C., Schwartzman S. et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology. 2020;59:3834–3844. https://doi.org/10.1093/rheumatology/keaa189; https://www.sibjcem.ru/jour/article/view/2645

  11. 11
    Academic Journal

    Συνεισφορές: 0

    Πηγή: Almanac of Clinical Medicine; Vol 53, No 1 (2025); 21-33 ; Альманах клинической медицины; Vol 53, No 1 (2025); 21-33 ; 2587-9294 ; 2072-0505

    Περιγραφή αρχείου: application/pdf

  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
    Academic Journal

    Πηγή: Российский кардиологический журнал, Vol 29, Iss 9 (2024)

    Περιγραφή αρχείου: electronic resource

    Σύνδεσμος πρόσβασης: https://doaj.org/article/6caaf5be46cc4ec290eb2b4753793051

  18. 18
  19. 19
    Academic Journal

    Συγγραφείς: Dodu, S.

    Πηγή: Buletinul Academiei de Ştiinţe a Moldovei: Ştiinţe Medicale, Vol 78, Iss 1, Pp 220-223 (2024)
    Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 78 (1) 220-223

    Περιγραφή αρχείου: application/pdf

  20. 20